直接或结合胆红素测量新生儿筛查胆道闭锁的诊断效能
IMPORTANCE: Treating biliary atresia in newborns earlier can delay or prevent the need for liver transplant; however, treatment typically occurs later because biliary atresia is difficult to detect during its early stages.…
要点
- 两阶段胆红素筛查可检出全部已知胆道闭锁病例,灵敏度100%但置信区间宽。
- 筛查实施后Kasai手术平均年龄由56天降至36天,提前19天。
- 阳性预测值仅5.9%,需关注假阳性负担与后续确诊流程。
核心结论
- 直接或结合胆红素两阶段新生儿筛查在研究中检出全部已知胆道闭锁婴儿,但灵敏度95%CI较宽,且研究设计未确保完全确认假阴性。
- 筛查实施与Kasai手术年龄显著提前相关,尚需更大样本研究评估诊断效能及成本效益。
研究设计与样本
- 前后对照研究纳入同一地区最大儿科肝病中心筛查实施前(2008年1月至2011年6月)43例接受Kasai手术的胆道闭锁婴儿中的24例,及实施后(2015年1月至2018年6月)的19例。
- 筛查为两阶段:第一阶段出生60小时内检测,阳性定义为超过推导的95百分位参考区间;第二阶段在2周健康访视时或之前复测,阳性定义为高于第一阶段结果或大于1 mg/dL。
主要发现
- 筛查检出7例已知胆道闭锁婴儿,灵敏度100%(95%CI 56.1%-100.0%),特异度99.9%(95%CI 99.9%-99.9%)。
- 阳性预测值5.9%(95%CI 2.6%-12.2%),阴性预测值100.0%(95%CI 100.0%-100.0%)。
关键数值与推荐
- 第一阶段筛查阳性:胆红素水平超过推导的95百分位参考区间。
- 第二阶段筛查阳性:胆红素水平大于第一阶段结果或大于1 mg/dL。
- 筛查阳性判定需两阶段均阳性,参考标准为地区儿科肝病中心诊断的胆道闭锁。
临床怎么用
- 在新生儿出生60小时内及2周健康访视时采用直接或结合胆红素进行两阶段筛查,可早期识别胆道闭锁。
- 筛查阳性婴儿需及时转诊至儿科肝病中心进一步确诊,以缩短Kasai手术等待时间。
局限性
- 灵敏度95%CI较宽(56.1%-100.0%),研究设计未确保完全确认假阴性结果。
- 阳性预测值较低(5.9%),可能增加假阳性相关负担。
- 需在更大规模人群中研究以获取更精确的诊断效能估计及临床结局与成本效益数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Treating biliary atresia in newborns earlier can delay or prevent the need for liver transplant; however, treatment typically occurs later because biliary atresia is difficult to detect during its early stages. OBJECTIVE: To determine the diagnostic yield of newborn screening for biliary atresia with direct or conjugated bilirubin measurements and to evaluate the association of screening implementation with clinical outcomes. DESIGN, SETTING, AND PARTICIPANTS: A cross-sectional screening study of 124 385 infants born at 14 Texas hospitals between January 2015 and June 2018; and a pre-post study of 43 infants who underwent the Kasai portoenterostomy as treatment for biliary atresia at the region's largest pediatric hepatology center before (January 2008-June 2011) or after (January 2015-June 2018) screening implementation. Final follow-up occurred on July 15, 2019. EXPOSURES: Two-stage screening with direct or conjugated bilirubin measurements. In stage 1, all newborns were tested within the first 60 hours of life, with a positive screening result defined as bilirubin levels exceeding derived 95th percentile reference intervals. In stage 2, infants who had a positive screening result in stage 1 were retested at or before the 2-week well-child visit, with a positive screening result defined as bilirubin levels greater than the stage 1 result or greater than 1 mg/dL. MAIN OUTCOMES AND MEASURES: The primary outcomes of the screening study were sensitivity, specificity, positive predictive value, and negative predictive value based on infants testing positive in both stages. The reference standard was biliary atresia diagnosed at the region's pediatric hepatology centers. The primary outcome of the pre-post study was the age infants underwent the Kasai portoenterostomy for treatment of biliary atresia. RESULTS: Of 124 385 newborns in the screening study, 49.2% were female, 87.6% were of term gestational age, 70.0% were white, and 48.1% were Hispanic. Screening identified the 7 known infants with biliary atresia with a sensitivity of 100% (95% CI, 56.1%-100.0%), a specificity of 99.9% (95% CI, 99.9%-99.9%), a positive predictive value of 5.9% (95% CI, 2.6%-12.2%), and a negative predictive value of 100.0% (95% CI, 100.0%-100.0%). In the pre-post study, 24 infants were treated before screening implementation and 19 infants were treated after screening implementation (including 6 of 7 from the screening study, 7 from screening at nonstudy hospitals, and 6 from referrals because of clinical symptoms). The age infants underwent the Kasai portoenterostomy was significantly younger after screening was implemented (mean age, 56 days [SD, 19 days] before screening implementation vs 36 days [SD, 22 days] after screening implementation; between-group difference, 19 days [95% CI, 7-32 days]; P = .004). CONCLUSIONS AND RELEVANCE: Newborn screening with direct or conjugated bilirubin measurements detected all known infants with biliary atresia in the study population, although the 95% CI around the sensitivity estimate was wide and the study design did not ensure complete ascertainment of false-negative results. Research is needed in larger populations to obtain more precise estimates of diagnostic yield and to better understand the clinical outcomes and cost-effectiveness of this screening approach.
引用
- Harpavat S, Garcia-Prats JA, Anaya C, et al. Diagnostic Yield of Newborn Screening for Biliary Atresia Using Direct or Conjugated Bilirubin Measurements. JAMA. 2020. PMID: 32207797. doi:10.1001/jama.2020.0837
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。